Recombinant Human CCND1 Protein，His

Cyclin D1 (CCND1) is a key regulatory protein involved in cell cycle progression, particularly in the transition from the G1 phase to the S phase. Abnormal expression or mutation of CCND1 has been associated with various cancers, including breast, lymphoma, and colorectal cancer, making it a significant focus in oncological research. The gene encoding CCND1 is often subjected to genetic alterations such as amplifications and translocations, which can lead to elevated protein levels and aberrant cell proliferation. Given its pivotal role in cellular proliferation and tumorigenesis, the study of CCND1 recombinant protein has garnered attention for both its potential as a biomarker and its utility in therapeutic approaches. Researchers have been investigating the structural and functional characteristics of the CCND1 protein to understand its interactions with cyclin-dependent kinases (CDKs) and other regulatory proteins within the cell cycle machinery. By producing recombinant CCND1, scientists can explore its biochemical properties, develop specific inhibitors, and assess its role in various signaling pathways, thereby paving the way for targeted cancer therapies. Additionally, studying CCND1's interaction with other cellular components could elucidate mechanisms of resistance to existing treatments, ultimately improving therapeutic regimens for cancer patients. Overall, the investigation of CCND1 recombinant protein serves as a crucial step toward unraveling the complexities of tumor biology and enhancing cancer treatment strategies.